Azatadine

Azatadine (Optimine) is a first-generation antihistamine and anticholinergic that was launched by Schering-Plough in 1973.[1][2]

Azatadine
Clinical data
Trade namesOptimine
AHFS/Drugs.comMicromedex Detailed Consumer Information
Pregnancy
category
  • US: B (No risk in non-human studies)
    ATC code
    Identifiers
    CAS Number
    PubChem CID
    IUPHAR/BPS
    DrugBank
    ChemSpider
    UNII
    KEGG
    ChEBI
    ChEMBL
    CompTox Dashboard (EPA)
    Chemical and physical data
    FormulaC20H22N2
    Molar mass290.410 g·mol−1
    3D model (JSmol)
      (verify)

    It was patented in 1967.[3] It has been succeeded by both loratadine and desloratadine.[4]:53 and marketing approvals have been widely withdrawn.[5][6][7][8]:290[9]

    See also

    References
    1. Katelaris, C. (1990). "Comparative effects of loratadine and azatadine in the treatment of seasonal allergic rhinitis". Asian Pacific Journal of Allergy and Immunology. 8 (2): 103–107. PMID 1982614.
    2. Small, P.; Barrett, D.; Biskin, N. (1990). "Effects of azatadine, terfenadine, and astemizole on allergen-induced nasal provocation". Annals of Allergy. 64 (2 Pt 1): 129–131. PMID 1968324.
    3. Azatadine, Villani, F. J.; Caldwell, W. U.S. Patent 3,326,924 (1967).
    4. Horak F. Antialergic and Vasoactive Drugs for Allergic Rhinitis. Chapter 4 in Allergy Frontiers:Therapy and Prevention. Volume 5 of Allergy Frontiers. Eds Pawankar R et al Springer Science & Business Media, 2010 ISBN 9784431993629
    5. Drugs.com Drugs.com listing for Azatadine Page accessed July 3, 2015
    6. Federal Register 2005 Food and Drug Administration Docket No.2005N-0058: Hospira, Inc. et al.; Withdrawal of Approval of 76 New Drug Applications and 60 Abbreviated New Drug Applications 70 FR 10651
    7. Federal Register 2007 Food and Drug Administration Docket No. 2004P-0262: Withdrawal of Approval of 128 Suitability Petitions 72 FR 8184
    8. Department of Economic and Social Affairs of the United Nations Secretariat Consolidated List of Products Whose Consumption and/or Sale Have Been Banned, Withdrawn, Severely Restricted or not Approved by Governments Twelfth Issue: Pharmaceuticals United Nations – New York, 2005
    9. FDA OGD Suitability Tracking Report (Sorted by Drug Name) Page accessed July 3, 2015


    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.